Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.48 Billion SEK | 125.11% |
| 2022 | 9.1 Billion SEK | -16.56% |
| 2021 | 10.9 Billion SEK | -25.15% |
| 2020 | 14.57 Billion SEK | -12.01% |
| 2019 | 16.56 Billion SEK | 553560.98% |
| 2018 | 2.99 Million SEK | -99.82% |
| 2017 | 1.65 Billion SEK | -41.17% |
| 2016 | 2.8 Billion SEK | 253.12% |
| 2015 | 795.15 Million SEK | 0.43% |
| 2014 | 791.77 Million SEK | 0.13% |
| 2013 | 790.77 Million SEK | 31.8% |
| 2012 | 600 Million SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 2.72 Billion SEK | 5354.6% |
| 2009 | 50 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 17.47 Billion SEK | 4.51% |
| 2024 Q2 | 17.09 Billion SEK | -11.05% |
| 2024 Q1 | 19.22 Billion SEK | -6.18% |
| 2023 Q4 | 20.48 Billion SEK | -2.76% |
| 2023 Q1 | 9.23 Billion SEK | 1.47% |
| 2023 Q3 | 21.06 Billion SEK | -25.25% |
| 2023 FY | 20.48 Billion SEK | 125.11% |
| 2023 Q2 | 28.18 Billion SEK | 205.2% |
| 2022 Q1 | 9.77 Billion SEK | -10.39% |
| 2022 Q3 | 10.18 Billion SEK | 3.35% |
| 2022 Q2 | 9.85 Billion SEK | 0.82% |
| 2022 FY | 9.1 Billion SEK | -16.56% |
| 2022 Q4 | 9.1 Billion SEK | -10.64% |
| 2021 Q1 | 13.7 Billion SEK | -5.92% |
| 2021 Q4 | 10.9 Billion SEK | -6.92% |
| 2021 Q3 | 11.71 Billion SEK | -0.86% |
| 2021 Q2 | 11.81 Billion SEK | -13.79% |
| 2021 FY | 10.9 Billion SEK | -25.15% |
| 2020 FY | 14.57 Billion SEK | -12.01% |
| 2020 Q1 | 15.44 Billion SEK | -6.73% |
| 2020 Q2 | 12.49 Billion SEK | -19.13% |
| 2020 Q3 | 13.31 Billion SEK | 6.59% |
| 2020 Q4 | 14.57 Billion SEK | 9.44% |
| 2019 Q3 | 9.06 Billion SEK | 51.83% |
| 2019 FY | 16.56 Billion SEK | 553560.98% |
| 2019 Q1 | 6.41 Billion SEK | 214243.03% |
| 2019 Q2 | 5.97 Billion SEK | -6.83% |
| 2019 Q4 | 16.56 Billion SEK | 82.6% |
| 2018 FY | 2.99 Million SEK | -99.82% |
| 2018 Q3 | 4 Million SEK | -20.0% |
| 2018 Q2 | 5 Million SEK | 0.0% |
| 2018 Q1 | 5 Million SEK | -99.7% |
| 2018 Q4 | 2.99 Million SEK | -25.23% |
| 2017 Q4 | 1.65 Billion SEK | 227.08% |
| 2017 Q3 | 505 Million SEK | 0.2% |
| 2017 Q2 | 504 Million SEK | 0.0% |
| 2017 Q1 | 504 Million SEK | -82.05% |
| 2017 FY | 1.65 Billion SEK | -41.17% |
| 2016 Q1 | 803 Million SEK | 0.99% |
| 2016 Q2 | 504 Million SEK | -37.24% |
| 2016 Q3 | 504 Million SEK | 0.0% |
| 2016 Q4 | 2.8 Billion SEK | 457.11% |
| 2016 FY | 2.8 Billion SEK | 253.12% |
| 2015 Q2 | 821 Million SEK | 0.24% |
| 2015 FY | 795.15 Million SEK | 0.43% |
| 2015 Q3 | 822 Million SEK | 0.12% |
| 2015 Q4 | 795.15 Million SEK | -3.27% |
| 2015 Q1 | 819 Million SEK | 3.44% |
| 2014 Q1 | 795.8 Million SEK | 0.64% |
| 2014 Q3 | 817.1 Million SEK | 0.05% |
| 2014 Q4 | 791.77 Million SEK | -3.1% |
| 2014 FY | 791.77 Million SEK | 0.13% |
| 2014 Q2 | 816.7 Million SEK | 2.63% |
| 2013 Q1 | 800.7 Million SEK | 33.45% |
| 2013 FY | 790.77 Million SEK | 31.8% |
| 2013 Q4 | 790.77 Million SEK | -0.63% |
| 2013 Q3 | 795.8 Million SEK | -0.69% |
| 2013 Q2 | 801.3 Million SEK | 0.07% |
| 2012 Q1 | 1.68 Billion SEK | 0.0% |
| 2012 Q2 | 1.05 Billion SEK | -37.14% |
| 2012 Q3 | 956.1 Million SEK | -9.52% |
| 2012 Q4 | 600 Million SEK | -37.25% |
| 2012 FY | 600 Million SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q1 | 2.75 Billion SEK | 1.1% |
| 2011 Q2 | 2.1 Billion SEK | -23.6% |
| 2011 Q3 | 1.99 Billion SEK | -5.24% |
| 2011 Q4 | - SEK | -100.0% |
| 2010 FY | 2.72 Billion SEK | 5354.6% |
| 2010 Q4 | 2.72 Billion SEK | -9.66% |
| 2010 Q3 | 3.01 Billion SEK | 108.45% |
| 2010 Q2 | 1.44 Billion SEK | -7.41% |
| 2010 Q1 | 1.56 Billion SEK | 3028.2% |
| 2009 Q4 | 50 Million SEK | 0.0% |
| 2009 FY | 50 Million SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | -232684.091% |
| Enzymatica AB (publ) | 26.1 Million SEK | -78377.57% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -4698294.495% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | -108103.042% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -432346.696% |
| Nanexa AB (publ) | 4.03 Million SEK | -507960.516% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | -4223.554% |
| Probi AB (publ) | 53.79 Million SEK | -37978.332% |
| Swedencare AB (publ) | 1.65 Billion SEK | -1135.078% |
| Toleranzia AB | 850 Thousand SEK | -2409900.0% |
| Vivesto AB | 8.16 Million SEK | -250695.788% |